EsoBiotec announced it has entered into a definitive agreement to be acquired by AstraZeneca (AZN). The EsoBiotec Engineered NanoBody ...

EsoBiotec’s platform has the potential to transform cell therapy by empowering the immune system to attack cancers ...

(Reuters) -Drugmaker AstraZeneca has agreed to buy biotechnology company EsoBiotec for up to $1 billion, it said on Monday, ...

AstraZeneca has struck a deal to acquire biotechnology EsoBiotec for up to $1bn, as the London-listed pharmaceuticals group ...

The deal includes the Belgian biotech’s vivo cell-therapy platform, which modifies immune cells within the patient’s body, ...

CAMBRIDGE, UK] Drugmaker AstraZeneca said on Monday (Mar 17) it will buy biotechnology firm EsoBiotec for up to US$1 billion.

EsoBiotec SA has entered into a definitive agreement to be acquired by AstraZeneca ( NASDAQ: AZN) for up to $1 billion, on a ...

AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1,000m, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, ...

AstraZeneca will acquire EsoBiotec for a total consideration of up to $1billion, on a cash and debt free basis. This will ...

Stocks in London are called to open flat on Monday, as investors digest plans by Chinese officials to boost consumption there, before focus later this week turns to central bank decisions. The US ...

American biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma ...

The AstraZeneca PLC ADR AZN advanced 1.42% to $77.60 Friday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index COMP rising 2.61% to ...